AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7774469 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐ELS + oral metoclopramide (n = 99)
Number of subjects: 329
Study 7774469 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sodium phosphate (n = 106)
Number of subjects: 329
Study 2330929 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold-recombinant bivalent A vaccine
Number of subjects: 189
Study 2330929 — intervention group
Group type: EXPERIMENTAL
Intervention: Trivalent inactivated vaccine
Number of subjects: 189
Study 6768270 — intervention group
Group type: EXPERIMENTAL
Intervention: Semi-upright position at 45 degrees in bed or early ambulation
Number of subjects: 90
Study 6768270 — intervention group
Group type: COMPARATOR
Intervention: Patients kept in bed
Number of subjects: 90
Study 6768270 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulatory patients
Number of subjects: 90
Study 31838622 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium and Ketamine (Mg + K)
Number of subjects: 60
Study 31838622 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (K)
Number of subjects: 60
Study 31838622 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 60
Study 30810700 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress imaging
Number of subjects: 8518
Study 30810700 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonimaging exercise tolerance test (ETT)
Number of subjects: 8518
Study 30810700 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary computed tomography angiography
Number of subjects: 8518
Study 28151412 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended hemodialysis hours (≥24 hours)
Number of subjects: 200
Study 28151412 — intervention group
Group type: COMPARATOR
Intervention: Standard hemodialysis hours (target 12‐15 hours, maximum 18 hours)
Number of subjects: 200
Study 26652098 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothbrush and toothpaste
Number of subjects: 30
Study 26652098 — intervention group
Group type: COMPARATOR
Intervention: Chlorhexidine solution and swab
Number of subjects: 30
Study 24299607 — intervention group
Group type: EXPERIMENTAL
Intervention: Xinfeng Capsule
Number of subjects: 100
Study 24299607 — intervention group
Group type: COMPARATOR
Intervention: Placebo (imitation leflunomide)
Number of subjects: 100
Study 24299607 — intervention group
Group type: COMPARATOR
Intervention: Placebo (imitation Xinfeng Capsule)
Number of subjects: 100
Study 21319908 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction intervention
Number of subjects: 697
Study 21319908 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual
Number of subjects: 697
Study 19165109 — intervention group
Group type: EXPERIMENTAL
Intervention: SilvaSorb Gel
Number of subjects: 24
Study 19165109 — intervention group
Group type: COMPARATOR
Intervention: Silvadene silver sulfadiazine cream
Number of subjects: 24
Study 17262140 — intervention group
Group type: COMPARATOR
Intervention: G1: glazed (control)
Number of subjects: 25
Study 17262140 — intervention group
Group type: EXPERIMENTAL
Intervention: G2: diamond bur finishing
Number of subjects: 25
Study 17262140 — intervention group
Group type: EXPERIMENTAL
Intervention: G3: G2 + silicon rubber tip polishing
Number of subjects: 25
Study 17262140 — intervention group
Group type: EXPERIMENTAL
Intervention: G4: G3 + felt disc/diamond polishing paste
Number of subjects: 25
Study 17262140 — intervention group
Group type: EXPERIMENTAL
Intervention: G5: G3 + felt disc impregnated with fine‐particle diamond paste
Number of subjects: 25
Study 12954578 — intervention group
Group type: EXPERIMENTAL
Intervention: Exemestane 25 mg/day
Number of subjects: 0
Study 12954578 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen 20 mg/day
Number of subjects: 0
Study 10859079 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonic J-pouch
Number of subjects: 47
Study 10859079 — intervention group
Group type: COMPARATOR
Intervention: Control (Straight coloanal anastomosis)
Number of subjects: 47
Study 9337167 — intervention group
Group type: EXPERIMENTAL
Intervention: Preincisional or intraincisional infiltration with metronidazole (0.915 g metronidazole disodium phosphate injection in 100 mL 0.9% normal saline, injected 60-80 mL into subcutaneous tissue and muscle).
Number of subjects: 239
Study 9337167 — intervention group
Group type: COMPARATOR
Intervention: Control group received intravenous injection of metronidazole disodium phosphate and cephazolin postoperatively.
Number of subjects: 239
Study 8441838 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine IV at 2 micrograms/kg/min in 0.45% NaCl at 100 mL/h for 2 h during and after cardiac catheterization
Number of subjects: 30
Study 8441838 — intervention group
Group type: COMPARATOR
Intervention: 0.45% NaCl IV at 100 mL/h (Group 1)
Number of subjects: 30
Study 8441838 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine IV at 2 micrograms/kg/min in 0.45% NaCl at 100 mL/h (Group 2)
Number of subjects: 30
Study 3154147 — intervention group
Group type: EXPERIMENTAL
Intervention: 16-week treatment program for wife assault
Number of subjects: 50
Study 30134136 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (1 g administered intravenously)
Number of subjects: 3891
Study 30134136 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3891
Study 27516409 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical practice
Number of subjects: 32
Study 27516409 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-light model
Number of subjects: 32
Study 27516409 — intervention group
Group type: EXPERIMENTAL
Intervention: Video model
Number of subjects: 32
Study 27516409 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 32
Study 23796946 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (2.2 g/day LC-n3-FA)
Number of subjects: 65
Study 23796946 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 22541046 — intervention group
Group type: EXPERIMENTAL
Intervention: Rupatadine 10 mg
Number of subjects: 30
Study 22541046 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 20724426 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukocyte filtration (n=20)
Number of subjects: 40
Study 20724426 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=20)
Number of subjects: 40
Study 20724426 — intervention group
Group type: EXPERIMENTAL
Intervention: In-vitro stimulated neutrophil responses
Number of subjects: 40
Study 20724426 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukocyte filtration
Number of subjects: 40
Study 19039554 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual technique for analyzing dynamic antral scintigraphy (DAS)
Number of subjects: 21
Study 19039554 — intervention group
Group type: COMPARATOR
Intervention: Automated technique (fast Fourier transform) for analyzing dynamic antral scintigraphy (DAS)
Number of subjects: 21
Study 19039554 — intervention group
Group type: EXPERIMENTAL
Intervention: Both manual and automated techniques
Number of subjects: 21
Study 15001305 — intervention group
Group type: EXPERIMENTAL
Intervention: Home IV therapy
Number of subjects: 82
Study 15001305 — intervention group
Group type: COMPARATOR
Intervention: Hospital IV therapy
Number of subjects: 82
Study 11336365 — intervention group
Group type: EXPERIMENTAL
Intervention: Hip arthroscopy (with or without debridement)
Number of subjects: 68
Study 9329413 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone (1 mg/kg per day orally) for 5 days
Number of subjects: 16
Study 9329413 — intervention group
Group type: COMPARATOR
Intervention: Healthy children (control group)
Number of subjects: 16
Study 9329413 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchodilator reversibility testing with albuterol
Number of subjects: 16
Study 7633086 — intervention group
Group type: EXPERIMENTAL
Intervention: Damp dusting
Number of subjects: 0
Study 7633086 — intervention group
Group type: COMPARATOR
Intervention: Non-damp dusting
Number of subjects: 0
Study 3130322 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive case management with additional funding for direct community services
Number of subjects: 0
Study 3130322 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive case management with expanded coverage of community services
Number of subjects: 0
Study 3130322 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 0
Study 29362512 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole (APZ) titrated to 15 mg
Number of subjects: 94
Study 29362512 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study 29362512 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole (APZ)
Number of subjects: 94
Study 26899003 — intervention group
Group type: EXPERIMENTAL
Intervention: Amniotic scaffold balloon after TCRA
Number of subjects: 57
Study 26899003 — intervention group
Group type: COMPARATOR
Intervention: Foley's balloon after TCRA
Number of subjects: 57
Study 26282845 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditional cash transfer (CCT) with nutrition education
Number of subjects: 40
Study 26282845 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 40
Study 23626800 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation (after 3 years)
Number of subjects: 532
Study 23626800 — intervention group
Group type: COMPARATOR
Intervention: Continuing smokers
Number of subjects: 532
Study 23626800 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifetime smoking burden
Number of subjects: 532
Study 23626800 — intervention group
Group type: EXPERIMENTAL
Intervention: Current cigarettes/day
Number of subjects: 532
Study 21181669 — intervention group
Group type: EXPERIMENTAL
Intervention: HPS (Human Patient Simulator)
Number of subjects: 92
Study 21181669 — intervention group
Group type: EXPERIMENTAL
Intervention: CD-ROM
Number of subjects: 92
Study 21181669 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 92
Study 18854693 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy
Number of subjects: 0
Study 18854693 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid artery stenting
Number of subjects: 0
Study 17149401 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational homecare program
Number of subjects: 80
Study 17149401 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 80
Study 15259929 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral Anterior Chamber Depth (PACD) measurement
Number of subjects: 490
Study 15259929 — intervention group
Group type: EXPERIMENTAL
Intervention: Central Anterior Chamber Depth (CACD) measurement
Number of subjects: 490
Study 15259929 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral Anterior Chamber Depth (PACD) and Central Anterior Chamber Depth (CACD) measurements
Number of subjects: 490
Study 10736981 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% ropivacaine
Number of subjects: 30
Study 10736981 — intervention group
Group type: COMPARATOR
Intervention: 0.5% bupivacaine
Number of subjects: 30
Study 9013228 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlormadinone acetate (100 mg/day)
Number of subjects: 14
Study 9013228 — intervention group
Group type: EXPERIMENTAL
Intervention: Flutamide (375 ng/day)
Number of subjects: 14
Study 9013228 — intervention group
Group type: EXPERIMENTAL
Intervention: LH-RH analogue
Number of subjects: 14
Study 1411081 — intervention group
Group type: EXPERIMENTAL
Intervention: Active electro-stimulator device
Number of subjects: 77
Study 1411081 — intervention group
Group type: COMPARATOR
Intervention: Placebo device
Number of subjects: 77
Study 4008128 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose marijuana cigarettes
Number of subjects: 0
Study 4008128 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose marijuana cigarettes
Number of subjects: 0
Study 4008128 — intervention group
Group type: COMPARATOR
Intervention: Placebo marijuana cigarettes
Number of subjects: 0
Study 30502284 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic Visual Feedback (VBF)
Number of subjects: 19
Study 30502284 — intervention group
Group type: COMPARATOR
Intervention: Without feedback
Number of subjects: 19
Study 29241617 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention led by female community health volunteers (FCHVs) with home visits every 4 months for lifestyle counselling and blood pressure monitoring.
Number of subjects: 1638
Study 29241617 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 1638
Study 27028911 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline (12-week oral course)
Number of subjects: 280
Study 27028911 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin plus hydroxychloroquine (12-week oral course)
Number of subjects: 280
Study 27028911 — intervention group
Group type: COMPARATOR
Intervention: Placebo (12-week course)
Number of subjects: 280
Study 24295850 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 day sequential therapy (SEQ)
Number of subjects: 357
Study 24295850 — intervention group
Group type: COMPARATOR
Intervention: 10 day modified bismuth quadruple therapy (QUAD)
Number of subjects: 357
Study 22281194 — intervention group
Group type: EXPERIMENTAL
Intervention: PA MDC group
Number of subjects: 100
Study 22281194 — intervention group
Group type: EXPERIMENTAL
Intervention: IA + PA MDC group
Number of subjects: 100
Study 22281194 — intervention group
Group type: COMPARATOR
Intervention: IA MDC group
Number of subjects: 100
Study 22281194 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100
Study 20131570 — intervention group
Group type: EXPERIMENTAL
Intervention: 20/50 blur level
Number of subjects: 124
Study 20131570 — intervention group
Group type: EXPERIMENTAL
Intervention: 20/100 blur level
Number of subjects: 124
Study 20131570 — intervention group
Group type: COMPARATOR
Intervention: 20/20 blur level
Number of subjects: 124
Study 18092206 — intervention group
Group type: EXPERIMENTAL
Intervention: Consanguineous populations
Number of subjects: 0
Study 18092206 — intervention group
Group type: EXPERIMENTAL
Intervention: Homozygote (‐alpha/‐alpha) children
Number of subjects: 0
Study 18092206 — intervention group
Group type: EXPERIMENTAL
Intervention: Homozygote (‐alpha/‐alpha) frequency
Number of subjects: 0
Study 18092206 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha(+)‐thalassemia allele frequency
Number of subjects: 0
Study 15470212 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid-artery stenting with an emboli-protection device
Number of subjects: 334
Study 15470212 — intervention group
Group type: COMPARATOR
Intervention: Endarterectomy
Number of subjects: 334
Study 11450675 — intervention group
Group type: EXPERIMENTAL
Intervention: Single 200-mg dose of doxycycline
Number of subjects: 482
Study 11450675 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 482
Study 9549926 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin
Number of subjects: 0
Study 9549926 — intervention group
Group type: COMPARATOR
Intervention: Phlebotomy
Number of subjects: 0
Study 9549926 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 0
Study 9549926 — intervention group
Group type: COMPARATOR
Intervention: Alpha-interferon and anagrelide
Number of subjects: 0
Study 9549926 — intervention group
Group type: COMPARATOR
Intervention: Antithrombotic drugs (e.g., aspirin)
Number of subjects: 0
Study 7798165 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual plasma exchange (PE)
Number of subjects: 41
Study 2903170 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium valproate (1600 mg/day) for 6 days
Number of subjects: 11
Study 30096258 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro activation of naive CD4+ T cells
Number of subjects: 18
Study 30096258 — intervention group
Group type: EXPERIMENTAL
Intervention: Regulatory T cells (Tregs)
Number of subjects: 18
Study 30096258 — intervention group
Group type: EXPERIMENTAL
Intervention: Age-related effects
Number of subjects: 18
Study 28768502 — intervention group
Group type: EXPERIMENTAL
Intervention: VolleyVeilig intervention (warm-up program with more than 50 distinct exercises)
Number of subjects: 0
Study 28768502 — intervention group
Group type: COMPARATOR
Intervention: Volleyball as usual (control group)
Number of subjects: 0
Study 26372583 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 minutes of additional outdoor activities added to each school day, with encouragement for parents to engage children in outdoor activities after school hours.
Number of subjects: 1903
Study 26372583 — intervention group
Group type: COMPARATOR
Intervention: Usual pattern of activity (control group).
Number of subjects: 1903
Study 26372583 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 minutes of additional outdoor activities added to each school day.
Number of subjects: 1903
Study 24239838 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactococcus lactis JCM5805 yogurt
Number of subjects: 0
Study 24239838 — intervention group
Group type: COMPARATOR
Intervention: Placebo yogurt
Number of subjects: 0
Study 20861820 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitriol
Number of subjects: 60
Study 20861820 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxercalciferol
Number of subjects: 60
Study 20861820 — intervention group
Group type: COMPARATOR
Intervention: Calcium carbonate
Number of subjects: 60
Study 20861820 — intervention group
Group type: COMPARATOR
Intervention: Sevelamer
Number of subjects: 60
Study 20861820 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitriol and Doxercalciferol
Number of subjects: 60
Study 18804486 — intervention group
Group type: EXPERIMENTAL
Intervention: Upright faces in frontal view
Number of subjects: 16
Study 18804486 — intervention group
Group type: EXPERIMENTAL
Intervention: Inverted faces in frontal view
Number of subjects: 16
Study 18804486 — intervention group
Group type: EXPERIMENTAL
Intervention: Upright faces varied in viewpoint (rotated 45 degrees)
Number of subjects: 16
Study 18804486 — intervention group
Group type: EXPERIMENTAL
Intervention: Inverted faces varied in viewpoint (rotated 45 degrees)
Number of subjects: 16
Study 16971821 — intervention group
Group type: COMPARATOR
Intervention: 12-week outpatient treatment
Number of subjects: 94
Study 16971821 — intervention group
Group type: EXPERIMENTAL
Intervention: PTSD treatment
Number of subjects: 94
Study 16971821 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperarousal PTSD symptoms improvement
Number of subjects: 94
Study 16971821 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporal course of symptom improvement
Number of subjects: 94
Study 14594917 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural treatment (CBT) programme
Number of subjects: 0
Study 14594917 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 0
Study 16143575 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitting position (Group 1, n=20)
Number of subjects: 40
Study 16143575 — intervention group
Group type: COMPARATOR
Intervention: Supine position (Group 2, n=20)
Number of subjects: 40
Study 10511327 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant supplementation (24 mg of beta-carotene, 1000 mg of ascorbate, and 800 IU of alpha-tocopherol daily for 12 weeks)
Number of subjects: 40
Study 10511327 — intervention group
Group type: COMPARATOR
Intervention: Placebo (baseline and post-treatment phases)
Number of subjects: 40
Study 7865226 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline (100 mg and 600 mg)
Number of subjects: 41
Study 7865226 — intervention group
Group type: EXPERIMENTAL
Intervention: Corynebacterium parvum (1 mg and 7 mg)
Number of subjects: 41
Study 2030255 — intervention group
Group type: EXPERIMENTAL
Intervention: LACTOSE
Number of subjects: 16
Study 2030255 — intervention group
Group type: COMPARATOR
Intervention: NOCHO
Number of subjects: 16
Study 2030255 — intervention group
Group type: COMPARATOR
Intervention: SUGAR
Number of subjects: 16
Study 2030255 — intervention group
Group type: EXPERIMENTAL
Intervention: Skim milk
Number of subjects: 16
Study 2030255 — intervention group
Group type: COMPARATOR
Intervention: Lactase-treated skim milk
Number of subjects: 16
Study 7286357 — intervention group
Group type: EXPERIMENTAL
Intervention: Clofazimine 100 mg daily with sun exposure
Number of subjects: 20
Study 7286357 — intervention group
Group type: EXPERIMENTAL
Intervention: Clofazimine 100 mg daily without sun exposure
Number of subjects: 20
Study 7286357 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 20
Study 27292774 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin (AMX) at 10 mg/kg body weight (b.w.)
Number of subjects: 0
Study 27292774 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin (AMX) at 20 mg/kg body weight (b.w.)
Number of subjects: 0
Study 26020589 — intervention group
Group type: EXPERIMENTAL
Intervention: Integration training (multisensory stimuli binding with tinnitus)
Number of subjects: 18
Study 26020589 — intervention group
Group type: COMPARATOR
Intervention: Attention diversion training (multisensory stimuli opposite side to tinnitus)
Number of subjects: 18
Study 23879519 — intervention group
Group type: EXPERIMENTAL
Intervention: Psoriasis group
Number of subjects: 30
Study 23879519 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy controls)
Number of subjects: 30
Study 22497062 — intervention group
Group type: EXPERIMENTAL
Intervention: SmokeCheck training program
Number of subjects: 165
Study 22497062 — intervention group
Group type: COMPARATOR
Intervention: Control group (waiting list)
Number of subjects: 165
Study 19608812 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosaprepitant 200 mg IV
Number of subjects: 0
Study 19608812 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400 mg per os
Number of subjects: 0
Study 19608812 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17512226 — intervention group
Group type: EXPERIMENTAL
Intervention: PTFE patch insertion
Number of subjects: 31
Study 17512226 — intervention group
Group type: EXPERIMENTAL
Intervention: Redo saphenofemoral ligation and great saphenous vein stripping with PTFE patch
Number of subjects: 31
Study 17512226 — intervention group
Group type: COMPARATOR
Intervention: Redo saphenofemoral ligation and great saphenous vein stripping without PTFE patch
Number of subjects: 31
Study 17512226 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (with and without PTFE patch)
Number of subjects: 31
Study 15180622 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 10 mg
Number of subjects: 2102